AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8092203 — intervention group
Group type: EXPERIMENTAL
Intervention: Median episiotomy
Number of subjects: 697
Study 8092203 — intervention group
Group type: COMPARATOR
Intervention: Intact perineum or spontaneous perineal tears
Number of subjects: 697
Study 8092203 — intervention group
Group type: COMPARATOR
Intervention: Intact perineum
Number of subjects: 697
Study 8092203 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous perineal tears
Number of subjects: 697
Study 8092203 — intervention group
Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 697
Study 8092203 — intervention group
Group type: COMPARATOR
Intervention: All perineal groups
Number of subjects: 697
Study 3378381 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg naloxone
Number of subjects: 0
Study 29413790 — intervention group
Group type: EXPERIMENTAL
Intervention: Prowling with proprioceptive training
Number of subjects: 32
Study 29413790 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 32
Study 28209466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavosonstat (N91115)
Number of subjects: 0
Study 28209466 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 25381314 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor screening for ischemic heart disease (IHD)
Number of subjects: 60915
Study 23562589 — intervention group
Group type: EXPERIMENTAL
Intervention: UCu200
Number of subjects: 1800
Study 23562589 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu380A
Number of subjects: 1800
Study 23562589 — intervention group
Group type: EXPERIMENTAL
Intervention: medicated γ-IUD
Number of subjects: 1800
Study 21493648 — intervention group
Group type: EXPERIMENTAL
Intervention: S/GSK1349572 50 mg with multivitamin (MVI; One A Day Maximum)
Number of subjects: 28
Study 21493648 — intervention group
Group type: EXPERIMENTAL
Intervention: S/GSK1349572 50 mg with liquid antacid (Maalox Advanced Maximum Strength)
Number of subjects: 28
Study 21493648 — intervention group
Group type: EXPERIMENTAL
Intervention: S/GSK1349572 50 mg 2 h before an antacid
Number of subjects: 28
Study 21493648 — intervention group
Group type: COMPARATOR
Intervention: S/GSK1349572 alone
Number of subjects: 28
Study 19625582 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based reminders to assess HIV risk behaviours or to offer HIV testing; feedback on adherence to reminders provided.
Number of subjects: 5
Study 19625582 — intervention group
Group type: COMPARATOR
Intervention: Control group providers tested 1.0% (n = 67) and 1.4% (n = 106) of patients in the preintervention and intervention period, respectively.
Number of subjects: 5
Study 19625582 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders to test for HIV versus reminders to perform risk assessment.
Number of subjects: 5
Study 17110827 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (3 g daily)
Number of subjects: 24
Study 17110827 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vegetable oil)
Number of subjects: 24
Study 15655266 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 64
Study 15655266 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 64
Study 11696730 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal 2% lidocaine gel
Number of subjects: 108
Study 11696730 — intervention group
Group type: COMPARATOR
Intervention: Intrarectal lubricant alone
Number of subjects: 108
Study 9127776 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS plus PGE1 (n = 45 patients)
Number of subjects: 86
Study 9127776 — intervention group
Group type: COMPARATOR
Intervention: PGE1 (n = 41 patients)
Number of subjects: 86
Study 2162027 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine serotype 3 (RRV) 10(5) pfu
Number of subjects: 96
Study 2162027 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine serotype 3 (RRV) 10(4) pfu
Number of subjects: 96
Study 2162027 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine serotype 3 (RRV) 10(3) pfu
Number of subjects: 96
Study 2162027 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula as buffer before vaccination (10(4) pfu group)
Number of subjects: 96
Study 2162027 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially breast-fed or formula-fed (10(4) pfu group)
Number of subjects: 96
Study 2162027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 386961 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium-169 citrate
Number of subjects: 24
Study 386961 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone acetate
Number of subjects: 24
Study 31126566 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentil savigh (roasted lentil flour) 30 grams daily (three 10-gram sachets in the morning)
Number of subjects: 54
Study 31126566 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid 500 mg every eight hours
Number of subjects: 54
Study 28754834 — intervention group
Group type: EXPERIMENTAL
Intervention: Management program comprising specialist review of care plans and nurse education in addition to usual care
Number of subjects: 563
Study 28754834 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 563
Study 28754834 — intervention group
Group type: EXPERIMENTAL
Intervention: Management program
Number of subjects: 563
Study 25871542 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroEclipse nebulizer
Number of subjects: 46
Study 25871542 — intervention group
Group type: COMPARATOR
Intervention: Wright nebulizer
Number of subjects: 46
Study 24636170 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation via intraoral approach with a single monocortical miniplate (group A)
Number of subjects: 0
Study 24636170 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation via extraoral approach with an inferior border plate (group B)
Number of subjects: 0
Study 22330824 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg V0191 once daily for 24 weeks
Number of subjects: 242
Study 22330824 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo once daily for 24 weeks
Number of subjects: 242
Study 20606093 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus cetuximab
Number of subjects: 745
Study 20606093 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine alone
Number of subjects: 745
Study 17617941 — intervention group
Group type: EXPERIMENTAL
Intervention: High tomato diet (400 ml tomato juice and 30 mg tomato ketchup daily)
Number of subjects: 21
Study 15616054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 15616054 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50
Study 12065987 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgical treatments for intervertebral disc herniation
Number of subjects: 1170
Study 12065987 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgical treatments for spinal stenosis
Number of subjects: 1170
Study 12065987 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgical treatments for degenerative spondylolisthesis
Number of subjects: 1170
Study 12065987 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatments for intervertebral disc herniation
Number of subjects: 1170
Study 12065987 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatments for spinal stenosis
Number of subjects: 1170
Study 12065987 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatments for degenerative spondylolisthesis
Number of subjects: 1170
Study 10188612 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-contoured cushion surface shapes generated with a seated-buttock contour gauge.
Number of subjects: 42
Study 10188612 — intervention group
Group type: COMPARATOR
Intervention: Flat foam cushions.
Number of subjects: 42
Study 8882120 — intervention group
Group type: EXPERIMENTAL
Intervention: Asbestos cement workers (30 subjects)
Number of subjects: 39
Study 8882120 — intervention group
Group type: EXPERIMENTAL
Intervention: Asbestos cement workers with effects related to asbestos (11 subjects with asbestosis)
Number of subjects: 39
Study 8882120 — intervention group
Group type: EXPERIMENTAL
Intervention: Asbestos cement workers with asbestosis (11 subjects)
Number of subjects: 39
Study 8882120 — intervention group
Group type: EXPERIMENTAL
Intervention: Asbestos cement workers with effects related to asbestos (11 subjects)
Number of subjects: 39
Study 8882120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cinescintigraphy
Number of subjects: 39
Study 8882120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cinescintigraphic variables
Number of subjects: 39
Study 1993636 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 25
Study 1993636 — intervention group
Group type: COMPARATOR
Intervention: Comparison groups
Number of subjects: 25
Study 6831838 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline administered intravenously prior to, during and/or after fatigue
Number of subjects: 3
Study 6831838 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 3
Study 29858393 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stents (LAMS)
Number of subjects: 60
Study 29858393 — intervention group
Group type: COMPARATOR
Intervention: Plastic stents
Number of subjects: 60
Study 29858393 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMS
Number of subjects: 60
Study 29452728 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention
Number of subjects: 235
Study 29452728 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 235
Study 29452728 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogates post-ACP intervention
Number of subjects: 235
Study 26307186 — intervention group
Group type: EXPERIMENTAL
Intervention: FORE-SIGHT ELITE cerebral oximeter
Number of subjects: 20
Study 26307186 — intervention group
Group type: COMPARATOR
Intervention: INVOS 5100C cerebral oximeter
Number of subjects: 20
Study 25092964 — intervention group
Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg
Number of subjects: 18
Study 25092964 — intervention group
Group type: COMPARATOR
Intervention: rizatriptan 10 mg
Number of subjects: 18
Study 25092964 — intervention group
Group type: EXPERIMENTAL
Intervention: frovatriptan
Number of subjects: 18
Study 22640983 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic model (age, parental/sibling history of diabetes, smoking status, body mass index, hypertension)
Number of subjects: 6342
Study 22640983 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model 1 (basic model + fasting plasma glucose, high-density lipoprotein-cholesterol, triglycerides)
Number of subjects: 6342
Study 22640983 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model 2 (clinical model 1 + glycated hemoglobin (HbA(1c)))
Number of subjects: 6342
Study 19640784 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS with 4mg nicotine
Number of subjects: 10
Study 19640784 — intervention group
Group type: COMPARATOR
Intervention: iTBS with placebo
Number of subjects: 10
Study 19640784 — intervention group
Group type: COMPARATOR
Intervention: Nicotine alone (control experiment)
Number of subjects: 10
Study 17487772 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 28
Study 17487772 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 28
Study 17487772 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 28
Study 17487772 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 28
Study 14678373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 115-1240 (1.5 mg twice daily for 2 or 4 weeks)
Number of subjects: 37
Study 14678373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 11743658 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 269
Study 11743658 — intervention group
Group type: COMPARATOR
Intervention: MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin)
Number of subjects: 269
Study 9434669 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team interventions in experimental homes
Number of subjects: 1854
Study 9434669 — intervention group
Group type: COMPARATOR
Intervention: Control homes
Number of subjects: 1854
Study 10628245 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotopic dim flash
Number of subjects: 70
Study 10628245 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotopic bright flash
Number of subjects: 70
Study 10628245 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker response
Number of subjects: 70
Study 2201425 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 58
Study 2201425 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 58
Study 2201425 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 58
Study 215795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam (PMPC) 200 mg per day
Number of subjects: 0
Study 215795 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid (NA) 2000 mg per day
Number of subjects: 0
Study 215795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam (PMPC)
Number of subjects: 0
Study 31657024 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%
Number of subjects: 32
Study 31657024 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 32
Study 31484770 — intervention group
Group type: EXPERIMENTAL
Intervention: Active instruction (following best practices in the discipline)
Number of subjects: 0
Study 31484770 — intervention group
Group type: COMPARATOR
Intervention: Passive instruction (lectures by experienced and highly rated instructors)
Number of subjects: 0
Study 28373701 — intervention group
Group type: EXPERIMENTAL
Intervention: Rd continuous
Number of subjects: 2993
Study 25423571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion (30 g glucose and 3 g 3‐O‐methylglucose)
Number of subjects: 28
Study 25423571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal glucose infusion
Number of subjects: 28
Study 25423571 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT‐1 expression
Number of subjects: 28
Study 24069753 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postpartum insertion (10 minutes to 48 hours)
Number of subjects: 115
Study 24069753 — intervention group
Group type: COMPARATOR
Intervention: 6 weeks postpartum insertion
Number of subjects: 115
Study 24069753 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction with the intrauterine device
Number of subjects: 115
Study 24069753 — intervention group
Group type: EXPERIMENTAL
Intervention: Feasibility of recruiting and consenting women
Number of subjects: 115
Study 21227548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (non-titrated, 9.5 mg/day for 3 months)
Number of subjects: 140
Study 21227548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch (titrated, 4.6 mg/day for 1 month followed by 9.5 mg/day for 2 months)
Number of subjects: 140
Study 21227548 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine capsules (6-12 mg/day for 3 months)
Number of subjects: 140
Study 19672164 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 300
Study 19672164 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 300
Study 19672164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dreamers (both groups)
Number of subjects: 300
Study 16112255 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate vaccine (MCC-TT)
Number of subjects: 106
Study 16112255 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib IgG geometric mean concentration (GMC)
Number of subjects: 106
Study 15131544 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (24-hour or 48-hour infusion)
Number of subjects: 7800
Study 15131544 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (48-hour infusion)
Number of subjects: 7800
Study 15131544 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 7800
Study 15131544 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7800
Study 11239100 — intervention group
Group type: EXPERIMENTAL
Intervention: Court-ordered treatment (78 participants)
Number of subjects: 142
Study 11239100 — intervention group
Group type: COMPARATOR
Intervention: Enhanced-service package only (64 participants)
Number of subjects: 142
Study 9404911 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin induction
Number of subjects: 96
Study 9404911 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandin E2 gel followed by oxytocin
Number of subjects: 96
Study 9404911 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 96
Study 8235813 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 208
Study 8235813 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 208
Study 2897462 — intervention group
Group type: EXPERIMENTAL
Intervention: Etintidine (400 mg)
Number of subjects: 12
Study 30499485 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser electrophoresis of herbal extracts (equisetum and hypericum)
Number of subjects: 44
Study 30499485 — intervention group
Group type: COMPARATOR
Intervention: NSAID-based anti-inflammatory therapy
Number of subjects: 44
Study 27538683 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized VRP700 (1.0 mg/kg)
Number of subjects: 8
Study 27538683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride 0.9%)
Number of subjects: 8
Study 24872365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon tears (painful rotator cuff tears)
Number of subjects: 0
Study 24872365 — intervention group
Group type: COMPARATOR
Intervention: Control tissue (posttraumatic shoulder instability)
Number of subjects: 0
Study 22339945 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia copings generated with the Procera system (group P)
Number of subjects: 60
Study 22339945 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia copings generated with the Lava system (group L)
Number of subjects: 60
Study 22339945 — intervention group
Group type: COMPARATOR
Intervention: Porcelain-fused-to-metal single-unit posterior FDPs (group C)
Number of subjects: 60
Study 20372053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccine (9 microg of haemagglutinin per strain)
Number of subjects: 2255
Study 20372053 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular control vaccine (15 microg haemagglutinin per strain)
Number of subjects: 2255
Study 20372053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccine
Number of subjects: 2255
Study 20372053 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular control vaccine
Number of subjects: 2255
Study 18930036 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces (negative emotional faces: angry and fearful)
Number of subjects: 14
Study 18930036 — intervention group
Group type: COMPARATOR
Intervention: Shapes (geometric shapes)
Number of subjects: 14
Study 16154479 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC MDI (salmeterol 25 microg, FPM 14 microg)
Number of subjects: 40
Study 16154479 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA MDI (salmeterol 25 microg, FPM 7 microg)
Number of subjects: 40
Study 16154479 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CFC MDI)
Number of subjects: 40
Study 16154479 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC MDI vs HFA MDI
Number of subjects: 40
Study 16154479 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC MDI and HFA MDI
Number of subjects: 40
Study 11989850 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral computed tomography (S-CT) assessment of tracheal stenoses
Number of subjects: 54
Study 11989850 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (no intervention)
Number of subjects: 54
Study 11989850 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom studies
Number of subjects: 54
Study 10435478 — intervention group
Group type: EXPERIMENTAL
Intervention: PEFc (corrected Peak Expiratory Flow)
Number of subjects: 57
Study 10435478 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1
Number of subjects: 57
Study 10435478 — intervention group
Group type: EXPERIMENTAL
Intervention: PEFnc (non-corrected Peak Expiratory Flow)
Number of subjects: 57
Study 7759396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 4.5 mg/kg/day, once daily
Number of subjects: 50
Study 7759396 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 4.5 mg/kg/day, thrice daily
Number of subjects: 50
Study 2186304 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Subcitrate (CBS, DE‐NOL)
Number of subjects: 0
Study 2186304 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (RN)
Number of subjects: 0
Study 4578364 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate 1.6 g daily
Number of subjects: 15000
Study 4578364 — intervention group
Group type: COMPARATOR
Intervention: Olive oil capsules (300-350 mg)
Number of subjects: 15000
Study 30264242 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement and hinged ankle distraction
Number of subjects: 50
Study 30264242 — intervention group
Group type: COMPARATOR
Intervention: Debridement alone
Number of subjects: 50
Study 28249847 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial question prompt list (QPL)
Number of subjects: 88
Study 28249847 — intervention group
Group type: COMPARATOR
Intervention: Control (no QPL)
Number of subjects: 88
Study 26619553 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndrome differentiation treatment group
Number of subjects: 81
Study 26619553 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment group
Number of subjects: 81
Study 26619553 — intervention group
Group type: COMPARATOR
Intervention: Disease differentiation treatment group
Number of subjects: 81
Study 26619553 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 81
Study 24479280 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus tea
Number of subjects: 6